Viking Therapeutics (VKTX) last week sued China-based Ascletis Bioscience (ASCLF) in California federal court, alleging Ascletis stole trade secrets related to its liver-disease drug candidate to develop its own competitor, Reuters reported. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Biotech Alert: Searches spiking for these stocks today
- Viking Therapeutics price target raised to $15 from $10 at Maxim
- Raymond James upgrades Madrigal to Market Perform after NASH data
- Madrigal’s data bodes well for Viking’s de-risked VK2809, says BTIG
- Trial success is rocketing this NASH stock higher and sinking these peers